🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma

RecruitingNAAges 18 Years - 50 YearsFemaleKasr El Aini Hospital
NCT07540702 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Melasma is a chronic acquired hyperpigmentation disorder that commonly affects the face and has a significant impact on quality of life. Available treatments may improve pigmentation, but relapse is common and response can be variable. This randomized split-face interventional study aims to compare the efficacy and safety of injectable platelet-rich fibrin (i-PRF) versus intradermal tranexamic acid (TA) in the treatment of facial melasma. Adult female patients with bilateral symmetrical facial melasma will be enrolled. In each participant, one side of the face will be randomly assigned to receive i-PRF and the contralateral side will receive intradermal TA. Patients will undergo five treatment sessions at 2-week intervals. Clinical response will be assessed using the modified Melasma Area and Severity Index (mMASI), Antera 3D camera measurements, Physician Global Assessment, patient sa

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type) * Female participants aged 18 to 50 years * Fitzpatrick skin types III to IV * Mild to moderate facial melasma * No melasma-specific treatment within the previous 4 weeks * No facial procedures, including peeling, laser resurfacing, or microneedling, within the previous 3 months * Willing and able to provide written informed consent and comply with study procedures Exclusion Criteria: * Pregnancy or lactation * Bleeding or coagulation disorders * Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception * Active skin infection or facial inflammation * History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo * Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease
💊

What it tests

  • Injectable Platelet-Rich Fibrin
  • Tranexamic acid 100 mg/mL (Kapron)
📍

Where

1 site
Kasr El Aini Hospital
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy